Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy

This publication has 43 references indexed in Scilit:

• Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes
  Proceedings of the National Academy of Sciences, 2012
• Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
  Cancer Research, 2011
• Advances in Liver Cancer Antibody Therapies
  BioDrugs, 2011
• Glypican-3: A new target for cancer immunotherapy
  European Journal of Cancer, 2011
• Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
  Clinical Cancer Research, 2009
• Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
  Journal of Clinical Oncology, 2009
• A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
  Blood, 2009
• Sorafenib in Advanced Hepatocellular Carcinoma
  New England Journal of Medicine, 2008
• Immunotoxin therapy of cancer
  Nature Reviews Cancer, 2006
• Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
  Hepatology, 2003